Philip Tsai

Philip Tsai appears in our data through filings on Immunome Inc. shares, published by SEC (Form 4). We count 4 filings; the first trade dates from 21 November 2024 and the latest from 23 July 2026.

The open-market record is one-sided, with 3 purchases worth €458k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant.

The median purchase comes to €175k. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

On 27 July 2026 came the latest disclosure, a share grant in Immunome Inc. The last purchase on record was published on 22 December 2025, which is 306 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.